1. Introduction to the Project

1.1 Introduction to technical achievements

KRAS mutations occur in about 25% of cancer cases, mainly in lung cancer, pancreatic cancer and colorectal cancer, and are associated with poor disease prognosis. Especially in the field of pancreatic cancer, 93% -95% of pancreatic cancer patients have KRAS gene mutation, a common pathogenic gene.

The research and development technology of KRAS PDE interaction inhibitors utilizes the idea of indirect inhibition of KRAS, and successfully constructs the KRAS selective inhibitor screening platform for protein interactions of KRAS and PDEδ based on carcinogenic mutations through the SERScreen technology platform, which has solved the current problems of difficult to develop drugs directly targeting KRAS targets and a single type of inhibitor. It provides a new high-throughput screening approach based on targets, promoting the development of cancer clinical treatment and pharmaceutical industry.

1.2 Technical analysis and advantages

1.2.1 Core technical analysis

The SERScreen drug screening technology platform is successfully utilized to build the high-throughput screening platform base on the protein interaction of KRAS-PDEδ and has successfully screened potential small molecule compounds for pancreatic cancer in the subsequent high-throughput screening of the combinatorial compound library, which is expected to solve the current situation that most KRAS mutation-related cancers are still incurable, and greatly promote the clinical treatment of cancer (such as pancreatic cancer, the king of cancer and colorectal cancer).

1.2.2 Technological innovation and advantages

This project involves 6 invention patents, of which 2 have been authorized and 4 are pending applications. It involves one authorized utility model patent.

1.3 Main products and applications of technical achievements

The main product of the project is KRAS-PDE interaction inhibitor, which belongs to the field of pharmaceutical technology and provides a new pyrimidine derivative for the preparation of anti-adenocarcinoma drugs and potential applications in other cancer drugs. This technical achievement shows that it has obvious selective inhibitory activity on KRAS oncogene mutant pancreatic cancer cells, and is used in the preparation of anticancer drugs.

1.4 Technical achievement commercialization and market promotion

1.4.1 Stage of technological achievements

The project has met the conditions for achievement commercialization.

1.4.2 Technical achievement marketing promotion plan

The target customers for the technical achievements of the project are mainly pharmaceutical companies, biotechnology companies, medical research institutions, etc.

Establishing a network: Create a dedicated website to introduce the research and development industrialization project of KRAS-PDE interaction inhibitors so that target customers can learn more relevant information and improve the project’s visibility and influence.

Attending exhibitions: Attend exhibitions and conferences in the fields of pharmaceuticals, biotechnology, medical research, etc., showcase the technology and achievements of the research and development industrialization project of KRAS-PDE interaction inhibitors, establish connections with target customers, and expand the market share of the project.

Carrying out publicity: Through various media channels such as press releases, industry magazines, social media, etc., we promote the technology and achievements of the research and development industrialization project of KRAS-PDE interaction inhibitors, and improve the project’s visibility and recognition.

Collaborative promotion: Collaborate with pharmaceutical companies, biotechnology companies, medical research institutions, and other partners to promote the research and development industrialization project of KRAS-PDE interaction inhibitors, and jointly explore the market.

Providing technical support: Provide technical support and services to target customers, establish good customer relationships, improve customer satisfaction and loyalty.

Based on market feedback and customer needs, it continuously improves the technology and products of the research and development industrialization project of KRAS-PDE interaction inhibitors, and enhance market competitiveness.

1.5 Technical team

The technical team of this project is the Modern Biology Research Group of the School of Pharmacy, Jilin University. In recent years, the team has mainly engaged in drug research and development, and has carried out a series of work in the field of drug screening using Raman spectroscopy technology. In the past five years, one of the developed varieties has been approved for clinical trials by the US FDA and one has been approved for clinical trials by the Chinese CDE.

The head of the research group is deeply involved in the interdisciplinary application fields of spectroscopy technology, drug development, and cell biology, and has collaborated with relevant professors from the School of Chemistry, Jilin University. The multidisciplinary research team is very stable. More than ten Chinese invention patents and one utility model patent have been authorized. It has hosted 1 National Natural Science Foundation project, 1 National Natural Science Foundation Youth Fund project, and 3 Jilin Provincial Department of Science and Technology projects. It has received the second prize of Jilin Province Science and Technology Progress Award.

2. Market Potential Analysis

KRAS mutations are widely present in Chinese cancer patients, and the market prospects for anti-tumor targeted drugs targeting KRAS mutations are broad. The KRAS mutation rate in the Chinese cancer population is 16.6%, and KRASG12C mutation accounts for 14.5% of KRAS mutations. The incidence of KRASG12C mutation is highest in lung cancer patients in the Chinese population, with 4.3% of patients carrying KRASG12C mutation. The next are colorectal cancer patients, with a KRASG12C mutation rate of 2.5%. In addition, the mutation rates of KRASG12C in bile duct cancer, endometrial cancer and pancreatic cancer were 2.3%, 1.4% and 0.9%, respectively

Pancreatic cancer is a kind of digestive tract malignant tumor with high malignancy and difficult diagnosis and treatment. It is known as the “king of cancer”. At present, there is a lack of specific drugs. The study found that KRAS gene mutation frequency was the highest in about 90% of pancreatic cancer. When KRAS undergoes a mutation, it will be in an “on” state, causing disruption of intracellular signal transduction and uncontrolled cell proliferation, leading to cancer. According to the publicly reported data, young patients with pancreatic cancer (<50 years old) are more likely to have non mutant KRAS gene. However, due to the difficulty in drug formation of targets, drug research and development progress is slow, while some targets with low mutation rate are ushering in breakthroughs: BRCA in pancreatic cancer, IDH1 or FGFR2 in biliary cancer. I hope to track the breakthrough process of potential targets by sorting out the progress of RAS targets.

Since the discovery of KRAS mutations in lung cancer over thirty years ago, significant progress has been made in the discovery of KRAS targeted drugs. Currently, clinical research is underway on various inhibitors, combination methods, and new alternative targeting methods. However, data on KRASG12C inhibitors shows that these drugs are far from achieving the expected therapeutic effects. But without a doubt, the development progress of KRASG12 inhibitors is the fastest, and some drugs have already entered the clinical practice stage. Conquering the KRAS mutation is a huge market demand, and according to statistics, it will be a market space of over 10 billion US dollars.

At the same time, the SERScreen drug screening technology platform can conduct mechanism research on other molecular interactions and screen small molecule drugs, serving users with corresponding needs, filling the gap in the relevant market, and promoting the development of molecular mechanism research and pharmaceutical industry.

3. Financing needs and financing purposes

The project is planned to raise 20 million yuan for production process development, quality research, pharmacological and pharmacological research, manpower and operations, intellectual property transfer, registration, and clinical trial scheme design.

4. Analysis of Technical Achievements and Benefits

4.1 Economic benefits

After the commercialization of the technological achievements, it is expected to achieve the global market revenue of around 200 million US dollars within one year.

4.2 Social benefits

The research and development project of KRAS-PDE interaction inhibitors has significant social benefits.

Firstly, KRAS-PDE interaction inhibitors are expected to bring revolutionary changes to cancer treatment. KRAS protein plays an important role in many types of cancer, but due to its complex structure and diverse regulatory mechanisms, it has long been considered untreatable. The emergence of KRAS-PDE interaction inhibitors may overcome this challenge and provide more effective treatment options for cancer patients.

Secondly, the research and development project of KRAS-PDE interaction inhibitors also helps to promote the development of China’s pharmaceutical industry. With the continuous progress of technology and competition in domestic and foreign markets, China’s pharmaceutical industry needs to constantly innovate and improve its research and development level to meet the growing health needs of the people. The research and development of KRAS-PDE interaction inhibitors is an important measure in line with this trend.

Finally, the research and development of KRAS-PDE interaction inhibitors will also help promote the development and research of related disciplines. For example, research on the structure and function of KRAS protein, as well as the regulatory mechanism of PDE enzyme, are currently hot and difficult topics in biological research. The study of KRAS-PDE interaction inhibitors will provide new ideas and experimental methods for research in these disciplines.

In summary, the research and development project of KRAS-PDE interaction inhibitors has important social benefits, which are expected to bring new hope to cancer treatment, promote the development of China’s pharmaceutical industry, and promote the research and development of related disciplines.

5. Contact Method:

Contact person: Xu Wan

Tel: 13756652164